V. Ramachandran, Inbakumar V., Kirankumar Hr, R. Tiwari, G. Tiwari
{"title":"Biochanin-A: Versatile Therapeutic Perspectives from Nature.","authors":"V. Ramachandran, Inbakumar V., Kirankumar Hr, R. Tiwari, G. Tiwari","doi":"10.2174/2589977514666220509201804","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nBiochanin-A (5,7 dihydroxy 4 methoxy isoflavone), a phytochemical phytoestrogen that serves as a protector/saviour of humans against various diseases. Biochanin-A is a nutritional and dietary isoflavonoid naturally present in red clover, chickpea, soybeans, etc, and various other herbs. The biochanin A possesses numerous biological activities.\n\n\nOBJECTIVE\nThe study focused on collective data of therapeutic activities of Biochanin-A.\n\n\nMETHOD\nAccording to the literature, Biochanin-A revealed range of activities starting from chemoprevention, by hindering cell growth, activation of tumor cell death, hampering metastasis, angiogenic action, cell cycle regulation, neuroprotection, by controlling microglial activation, balancing antioxidants, elevating the neurochemicals, suppressing BACE-1, NADPH oxidase hindrance to inflammation, by mitigating the MAPK and NF- ĸB, discharge of inflammatory markers, up-regulating the PPAR-γ, improving the function of heme oxygenase-1, erythroid 2 nuclear factors, detoxifying the oxygen radicals and stimulating the superoxide dismutase action, and controlling its production of transcription factors. Against pathogens, biochanin-A acts by dephosphorylating tyrosine kinase proteins, obstructing gram-negative bacteria, suppressing the cytokines development from viruses, improving the action of a neuraminidase inhibitor, cleavage of caspase-3, and acts as an efflux pump inhibitor. In metabolic disorders, biochanin-A acts by encouraging transcriptional initiation and inhibition, activating estrogen receptors, increasing the activity of differentiation, autophagy, inflammation, and metabolism of blood glucose.\n\n\nCONCLUSION\nTherefore, biochanin-A could be used as a therapeutic drug for various pathological conditions and treatments in humans.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Research Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2589977514666220509201804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
Abstract
BACKGROUND
Biochanin-A (5,7 dihydroxy 4 methoxy isoflavone), a phytochemical phytoestrogen that serves as a protector/saviour of humans against various diseases. Biochanin-A is a nutritional and dietary isoflavonoid naturally present in red clover, chickpea, soybeans, etc, and various other herbs. The biochanin A possesses numerous biological activities.
OBJECTIVE
The study focused on collective data of therapeutic activities of Biochanin-A.
METHOD
According to the literature, Biochanin-A revealed range of activities starting from chemoprevention, by hindering cell growth, activation of tumor cell death, hampering metastasis, angiogenic action, cell cycle regulation, neuroprotection, by controlling microglial activation, balancing antioxidants, elevating the neurochemicals, suppressing BACE-1, NADPH oxidase hindrance to inflammation, by mitigating the MAPK and NF- ĸB, discharge of inflammatory markers, up-regulating the PPAR-γ, improving the function of heme oxygenase-1, erythroid 2 nuclear factors, detoxifying the oxygen radicals and stimulating the superoxide dismutase action, and controlling its production of transcription factors. Against pathogens, biochanin-A acts by dephosphorylating tyrosine kinase proteins, obstructing gram-negative bacteria, suppressing the cytokines development from viruses, improving the action of a neuraminidase inhibitor, cleavage of caspase-3, and acts as an efflux pump inhibitor. In metabolic disorders, biochanin-A acts by encouraging transcriptional initiation and inhibition, activating estrogen receptors, increasing the activity of differentiation, autophagy, inflammation, and metabolism of blood glucose.
CONCLUSION
Therefore, biochanin-A could be used as a therapeutic drug for various pathological conditions and treatments in humans.